Search results
Author(s):
Ton Duy Mai
,
Tri Huynh Quang Ho
,
Sy Van Hoang
,
et al
Added:
1 month ago
Author(s):
Monika Bhandari
,
Akshyaya Pradhan
,
Pravesh Vishwakarma
,
et al
Added:
4 months ago
ESC 23: The RIGHT Study
Author(s):
Yan Yan
,
Gilles Montalescot
Added:
1 year ago
Video
Author(s):
Paulus Kirchhof
Added:
1 year ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577).
NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,…
View more
Author(s):
Minh That Ton
,
Tri Huynh Quang Ho
,
Viet Lan Nguyen
,
et al
Added:
1 year ago
AHA 24: The OPTION Trial
Author(s):
Oussama M Wazni
Added:
6 months ago
Video
Author(s):
Tri Huynh Quang Ho
,
Minh That Ton
,
Viet Lan Nguyen
,
et al
Added:
1 year ago
Author(s):
Mario DiazNuila-Alcazar
,
Daniel Valcárcel-Paz
,
Pablo Del Castillo-Vásquez
,
et al
Added:
9 months ago
Author(s):
Apisara Lohachatinante
,
Nuttanun Kittikunkanyakit
,
Sayamon Sukkha
,
et al
Added:
11 months ago
Author(s):
Julius Nikorowitsch
Added:
1 year ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from…
View more